Regenxbio Inc (FRA:RB0)
€ 7.05 0 (0%) Market Cap: 350.57 Mil Enterprise Value: 186.24 Mil PE Ratio: 0 PB Ratio: 1.29 GF Score: 59/100

Regenxbio Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2020 / 12:45PM GMT
Release Date Price: €23.9 (+5.52%)
Matthew Harrison

Great. Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley.

Quickly, before we get started with REGENX, I just need to read a brief disclaimer. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you're a member of the press, please disconnect and reach out separately.

For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to Morgan Stanley sales representatives.

So with that, very pleased to have the team from REGENXBIO with me, Ken Mills, the CEO; and Steve Pakola, who is the CMO.

And I guess I thought we should probably just get started with wet AMD and what you're doing there. Maybe a good place to start is you're obviously looking at multiple delivery mechanisms now. So maybe just talk a little bit about the data that you have and the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot